CONCLUSIONS
asthma, allergic disease
ASTHMA
Several clinical trials and observational studies have proven that SCIT with Depigoid® HDM extract is safe and efficacious,This study has some limitations, such as the number of patients, which is especially small when splitting between two treatment groups; however, the level of significance is very high and therefore we believe these findings are robust. Given the retrospective study design, some variables were not consistent between the initial clinical trial and the current retrospective study; however, symptom and MS, commonly used to measure efficacy in clinical trials, have been evaluated in both studies. We do believe that better‐designed long‐term prospective studies are required to confirm these findings. The lack of control group can be considered a limitation, however, ethically is difficult to avoid patients from accessing the only treatment that has proven to modify the natural course of the allergic disease for such a long period of time, to be included in a control group.In general, these results suggest that AIT treatment duration of ≥3 years is cost‐effective as an important percent of patients remain asymptomatic and do not require rescue medication including asthma treatment, although specific studies are needed.Given that long‐term studies (observation period after more than 5 years of AIT treatment discontinuation) are very scarce, these results help to support the international guidelines recommendation that a minimum of 3 years of AIT treatment is required for a sustained long‐term effect.